Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NADIR trial (niraparib): what clinicians have said so far
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
- NCT04037254 ↗
- Completed
- NRG Oncology
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NADIR (niraparib in high-risk prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NADIR so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Prostate Adenocarcinoma; Stage IIC Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
- Interventions
- Gonadotrophin Releasing Hormone; Intensity-Modulated Radiation Therapy; Niraparib
- Arms
- Phase I, Dose Level 1 (niraparib, GnRH, IMRT) · Experimental
- Phase I, Dose Level 2 (niraparib, GnRH, IMRT) · Experimental
- Phase I, Dose Level 3 (niraparib, GnRH, IMRT) · Experimental
- Phase II, Arm I (GnRH, IMRT) · Active comparator
- Phase II, Arm II (niraparib, GnRH, IMRT) · Experimental
- Enrollment
- 22
- Primary outcomes
- Number of Participants Disease-free Until Completion of Treatment (2 Years From Start of ADT)
- Sponsor
- NRG Oncology with National Cancer Institute (NCI)
- Start
- Oct 8, 2019
- Primary completion
- Jul 1, 2024
- Results posted
- Yes
- Registry record
- NCT04037254 · updated Jul 10, 2026